Modeling approach to estimate the Gross Domestic Product of sponsored clinical trials in Colombia
DOI:
https://doi.org/10.18046/j.estger.2026.178.8322Keywords:
clinical trials, gross domestic product, gross value added, Colombia, research and developmentAbstract
Our objective is to estimate the Gross Domestic Product (GDP) and Gross Value Added of the industry‑sponsored clinical trials sector in Colombia for 2023 and 2024. A modeling approach was developed to estimate revenues and expenses for research sites, sponsors, and ethics committees, using data from national and international registries as the primary independent variable. The results indicate a sectoral contribution of 0.01% to the national GDP and 0.34% to the Health Sector GDP, generating USD 73.2 million in service exports. The study concludes that clinical trials constitute a strategic economic activity and a robust source of foreign investment that should be prioritized in public policy.
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Estudios Gerenciales
This work is licensed under a Creative Commons Attribution 4.0 International License.
Articles are the sole responsibility of their authors, and will not compromise Icesi’s University principles or policies nor those of the Editorial Board of the journal Estudios Gerenciales. Authors authorize and accept the transfer of all rights to the journal, both for its print and electronic publication. After an article is published, it may be reproduced without previous permission of the author or the journal but the author(s), year, title, volume, number and range of pages of the publication must be mentioned. In addition, Estudios Gerenciales must be mentioned as the source (please, refrain from using Revista Estudios Gerenciales).
